Expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition)

Expert group of expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition)

doi:10.19401/j.cnki.1007-3639.2022.01.011

您当前的位置：

首页 >

文章列表页 >

Expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition)

Guideline and Consensus | 更新时间：2025-12-31

- Expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition)
- China Oncology Vol. 32, Issue 1, Pages: 80-89(2022)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.01.011
  CLC： R737.9
- Received：18 December 2021，
  
  Published：30 January 2022
- 稿件说明：
移动端阅览
Expert group of expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition). Expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition)[J]. China Oncology, 2022, 32(1): 80-89.
DOI：

Expert group of expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition). Expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition)[J]. China Oncology, 2022, 32(1): 80-89. DOI： 10.19401/j.cnki.1007-3639.2022.01.011.

摘要

新辅助治疗已经成为乳腺癌综合治疗中非常重要的组成部分

2019年中国乳腺癌新辅助治疗专家组就新辅助治疗的目的、适应证、评估规范、手术治疗原则及新辅助系统治疗的策略进行了详细探讨和阐述

结合近两年新的循证医学证据和学术理念

对新辅助治疗临床实施规范和治疗原则予以更新和说明。

Abstract

Neoadjuvant therapy has become one of the standard treatments in early breast cancer. In 2019

China breast cancer neoadjuvant therapy expert group discussed and expounded the purpose

indication

evaluation criteria

surgical operation principles and the treatment strategy of neoadjuvant therapy. We further updated and discussed the clinical implementations and treatment principles of neoadjuvant therapy.

关键词

Keywords

references

中国乳腺癌新辅助治疗专家组 . 中国乳腺癌新辅助治疗专家共识(2019年版) [J ] . 中国癌症杂志 , 2019 , 29 ( 5 ): 390 - 400 .

China Breast Cancer Neoadjuvant Therapy Expert Group . Expert consensus on neoadjuvant therapy for breast cancer in China (2019 edition) [J ] . China Oncol , 2019 , 29 ( 5 ): 390 - 400 .

KORDE L A , SOMERFIELD M R , CAREY L A , et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline [J ] . J Clin Oncol , 2021 , 39 ( 13 ): 1485 - 1505 . DOI: 10.1200/JCO.20.03399 http://doi.org/10.1200/JCO.20.03399 https://ascopubs.org/doi/10.1200/JCO.20.03399 https://ascopubs.org/doi/10.1200/JCO.20.03399

BURSTEIN H J , CURIGLIANO G , THÜRLIMANN B , et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 [J ] . Ann Oncol , 2021 , 32 ( 10 ): 1216 - 1235 . DOI: 10.1016/j.annonc.2021.06.023 http://doi.org/10.1016/j.annonc.2021.06.023 https://linkinghub.elsevier.com/retrieve/pii/S0923753421021049 https://linkinghub.elsevier.com/retrieve/pii/S0923753421021049

中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 10 ): 954 - 1040 .

The Society of Breast Cancer China Anti-Cancer Association . Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2021 edition) [J ] . China Oncol , 2021 , 31 ( 10 ): 954 - 1040 .

BOUGHEY J C , SUMAN V J , MITTENDORF E A , et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial [J ] . JAMA , 2013 , 310 ( 14 ): 1455 - 1461 . DOI: 10.1001/jama.2013.278932 http://doi.org/10.1001/jama.2013.278932 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.278932 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.278932

BRACKSTONE M , BALDASSARRE F G , PERERA F E , et al. Management of the axilla in early-stage breast cancer: Ontario health (cancer care Ontario) and ASCO guideline [J ] . J Clin Oncol , 2021 , 39 ( 27 ): 3056 - 3082 . DOI: 10.1200/JCO.21.00934 http://doi.org/10.1200/JCO.21.00934 https://ascopubs.org/doi/10.1200/JCO.21.00934 https://ascopubs.org/doi/10.1200/JCO.21.00934

JUNG S Y , HAN J H , PARK S J , et al. The sentinel lymph node biopsy using indocyanine green fluorescence plus radioisotope method compared with the radioisotope-only method for breast cancer patients after neoadjuvant chemotherapy: a prospective, randomized, open-label, single-center phase 2 trial [J ] . Ann Surg Oncol , 2019 , 26 ( 8 ): 2409 - 2416 . DOI: 10.1245/s10434-019-07400-0 http://doi.org/10.1245/s10434-019-07400-0 https://doi.org/10.1245/s10434-019-07400-0 https://doi.org/10.1245/s10434-019-07400-0

MAMTANI A , BARRIO A V , KING T A , et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study [J ] . Ann Surg Oncol , 2016 , 23 ( 11 ): 3467 - 3474 . DOI: 10.1245/s10434-016-5246-8 http://doi.org/10.1245/s10434-016-5246-8 http://link.springer.com/10.1245/s10434-016-5246-8 http://link.springer.com/10.1245/s10434-016-5246-8

《乳腺癌新辅助治疗的病理诊断专家共识2020版》编写组 . 乳腺癌新辅助治疗的病理诊断专家共识(2020版) [J ] . 中华病理学杂志 , 2020 , 49 ( 4 ): 296 - 304 .

Writing Group of Expert Panel Consensus on Pathological Diagnosis of Breast Cancer with Neoadjuvant Therapy, the 2020 Version . Expert panel consensus on pathological diagnosis of breast cancer with neoadjuvant therapy, the 2020 version [J ] . Chin J Pathol , 2020 , 49 ( 4 ): 296 - 304 .

EL-DIDI M H , MONEER M M , KHALED H M , et al. Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management [J ] . Surg Today , 2000 , 30 ( 3 ): 249 - 254 . DOI: 10.1007/s005950050054 http://doi.org/10.1007/s005950050054 http://link.springer.com/10.1007/s005950050054 http://link.springer.com/10.1007/s005950050054

HARBECK N , GLUZ O , CHRISTGEN M , et al. De-escalation strategies in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (BC): final analysis of the west German study group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2 - and hormone receptor-positive phase & #x02161; randomized trial-efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET [J ] . J Clin Oncol , 2017 , 35 ( 26 ): 3046 - 3054 . DOI: 10.1200/JCO.2016.71.9815 http://doi.org/10.1200/JCO.2016.71.9815 https://ascopubs.org/doi/10.1200/JCO.2016.71.9815 https://ascopubs.org/doi/10.1200/JCO.2016.71.9815

PÉREZ-GARCÍA J M , GEBHART G , RUIZ BORREGO M , et al. Chemotherapy de-escalation using an 18 F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial [J ] . Lancet Oncol , 2021 , 22 ( 6 ): 858 - 871 . DOI: 10.1016/S1470-2045(21)00122-4 http://doi.org/10.1016/S1470-2045(21)00122-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204521001224 https://linkinghub.elsevier.com/retrieve/pii/S1470204521001224

LOIBL S , UNTCH M , BURCHARDI N , et al. A randomised phase Ⅱ study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study [J ] . Ann Oncol , 2019 , 30 ( 8 ): 1279 - 1288 . DOI: 10.1093/annonc/mdz158 http://doi.org/10.1093/annonc/mdz158 https://linkinghub.elsevier.com/retrieve/pii/S0923753419312785 https://linkinghub.elsevier.com/retrieve/pii/S0923753419312785

MITTENDORF E A , ZHANG H , BARRIOS C H , et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial [J ] . Lancet , 2020 , 396 ( 10257 ): 1090 - 1100 . DOI: 10.1016/S0140-6736(20)31953-X http://doi.org/10.1016/S0140-6736(20)31953-X https://linkinghub.elsevier.com/retrieve/pii/S014067362031953X https://linkinghub.elsevier.com/retrieve/pii/S014067362031953X

SCHMID P , CORTES J , PUSZTAI L , et al. Pembrolizumab for early triple-negative breast cancer [J ] . N Engl J Med , 2020 , 382 ( 9 ): 810 - 821 . DOI: 10.1056/NEJMoa1910549 http://doi.org/10.1056/NEJMoa1910549 http://www.nejm.org/doi/10.1056/NEJMoa1910549 http://www.nejm.org/doi/10.1056/NEJMoa1910549

POGGIO F , BRUZZONE M , CEPPI M , et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis [J ] . Ann Oncol , 2018 , 29 ( 7 ): 1497 - 1508 . DOI: 10.1093/annonc/mdy127 http://doi.org/10.1093/annonc/mdy127 https://linkinghub.elsevier.com/retrieve/pii/S0923753419320988 https://linkinghub.elsevier.com/retrieve/pii/S0923753419320988

ELLIS M J , SUMAN V J , HOOG J , et al. Ki-67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology group Z1031 trial (alliance) [J ] . J Clin Oncol , 2017 , 35 ( 10 ): 1061 - 1069 . DOI: 10.1200/JCO.2016.69.4406 http://doi.org/10.1200/JCO.2016.69.4406 https://ascopubs.org/doi/10.1200/JCO.2016.69.4406 https://ascopubs.org/doi/10.1200/JCO.2016.69.4406

NITZ U , GLUZ O , KREIPE H H , et al. The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer [J ] . Ther Adv Med Oncol , 2020 , 12 : 1758835920973130 .

SCHNEEWEISS A , CHIA S , HICKISH T , et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA) [J ] . Ann Oncol , 2013 , 24 ( 9 ): 2278 - 2284 . DOI: 10.1093/annonc/mdt182 http://doi.org/10.1093/annonc/mdt182 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369297 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369297

HURVITZ S A , MARTIN M , JUNG K H , et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase Ⅲ KRISTINE study [J ] . J Clin Oncol , 2019 , 37 ( 25 ): 2206 - 2216 . DOI: 10.1200/JCO.19.00882 http://doi.org/10.1200/JCO.19.00882 https://ascopubs.org/doi/10.1200/JCO.19.00882 https://ascopubs.org/doi/10.1200/JCO.19.00882

VAN RAMSHORST M S , VAN DER VOORT A , VAN WERKHOVEN E D , et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial [J ] . Lancet Oncol , 2018 , 19 ( 12 ): 1630 - 1640 . DOI: 10.1016/S1470-2045(18)30570-9 http://doi.org/10.1016/S1470-2045(18)30570-9 https://linkinghub.elsevier.com/retrieve/pii/S1470204518305709 https://linkinghub.elsevier.com/retrieve/pii/S1470204518305709

NCCN Clinical Practice Guidelines in Oncology-Breast Cancer (Version 8 2021) [M ] . 2021 .

MASUDA N , LEE S J , OHTANI S , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy [J ] . N Engl J Med , 2017 , 376 ( 22 ): 2147 - 2159 . DOI: 10.1056/NEJMoa1612645 http://doi.org/10.1056/NEJMoa1612645 http://www.nejm.org/doi/10.1056/NEJMoa1612645 http://www.nejm.org/doi/10.1056/NEJMoa1612645

VON MINCKWITZ G , HUANG C S , MANO M S , et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer [J ] . N Engl J Med , 2019 , 380 ( 7 ): 617 - 628 . DOI: 10.1056/NEJMoa1814017 http://doi.org/10.1056/NEJMoa1814017 http://www.nejm.org/doi/10.1056/NEJMoa1814017 http://www.nejm.org/doi/10.1056/NEJMoa1814017

VON MINCKWITZ G , BLOHMER J U , COSTA S D , et al. Response-guided neoadjuvant chemotherapy for breast cancer [J ] . J Clin Oncol , 2013 , 31 ( 29 ): 3623 - 3630 . DOI: 10.1200/JCO.2012.45.0940 http://doi.org/10.1200/JCO.2012.45.0940 http://ascopubs.org/doi/10.1200/JCO.2012.45.0940 http://ascopubs.org/doi/10.1200/JCO.2012.45.0940

CROSHAW R , SHAPIRO-WRIGHT H , SVENSSON E , et al. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients [J ] . Ann Surg Oncol , 2011 , 18 ( 11 ): 3160 - 3163 . DOI: 10.1245/s10434-011-1919-5 http://doi.org/10.1245/s10434-011-1919-5 http://link.springer.com/10.1245/s10434-011-1919-5 http://link.springer.com/10.1245/s10434-011-1919-5

GIANNI L , EIERMANN W , SEMIGLAZOV V , et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort [J ] . Lancet , 2010 , 375 ( 9712 ): 377 - 384 . DOI: 10.1016/S0140-6736(09)61964-4 http://doi.org/10.1016/S0140-6736(09)61964-4 https://linkinghub.elsevier.com/retrieve/pii/S0140673609619644 https://linkinghub.elsevier.com/retrieve/pii/S0140673609619644

GIANNI L , PIENKOWSKI T , IM Y H , et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J ] . Lancet Oncol , 2016 , 17 ( 6 ): 791 - 800 . DOI: 10.1016/S1470-2045(16)00163-7 http://doi.org/10.1016/S1470-2045(16)00163-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204516001637 https://linkinghub.elsevier.com/retrieve/pii/S1470204516001637

JOHNSTON S R D , HARBECK N , HEGG R , et al. Abemaciclib combined with endocrine therapy for the adjuvant tre atment of HR + , HER2 - , node-positive, high-risk, early breast cancer (monarchE) [J ] . J Clin Oncol , 2020 , 38 ( 34 ): 3987 - 3998 . DOI: 10.1200/JCO.20.02514 http://doi.org/10.1200/JCO.20.02514 https://ascopubs.org/doi/10.1200/JCO.20.02514 https://ascopubs.org/doi/10.1200/JCO.20.02514

MAYER I A , ZHAO F M , ARTEAGA C L , et al. Randomized phase Ⅲ postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131 [J ] . J Clin Oncol , 2021 , 39 ( 23 ): 2539 - 2551 . DOI: 10.1200/JCO.21.00976 http://doi.org/10.1200/JCO.21.00976 https://ascopubs.org/doi/10.1200/JCO.21.00976 https://ascopubs.org/doi/10.1200/JCO.21.00976

LOIBL S , MARMÉ F , MARTIN M , et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial [J ] . J Clin Oncol , 2021 , 39 ( 14 ): 1518 - 1530 . DOI: 10.1200/JCO.20.03639 http://doi.org/10.1200/JCO.20.03639 https://ascopubs.org/doi/10.1200/JCO.20.03639 https://ascopubs.org/doi/10.1200/JCO.20.03639

Views

4965

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Expert consensus on BRCA1/2 gene testing and clinical application in Chinese breast cancer patients (2025 edition)

Research progress of axillary de-escalation management after neoadjuvant chemotherapy for clinical lymph node positive patients

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

A study of 30-year trends in incidence and mortality risks of breast cancer among young women in China

Related Author

Hongxia WANG

Yongmei YIN

Xichun HU

Qingda FAN

Binbin CONG

Yuguang CHEN

Baowei DUAN

Yongsheng WANG

Related Institution

Committee of Breast Cancer Society, Chinese Anti-Cancer Association; Clinical Precision Medicine Professional Committee, Chinese Medical Doctor Association; Tumor Heterogeneity and Personalized Therapy Professional Committee, Chinese Anti-Cancer Association

Graduate Department of Shandong First Medical University and Shandong Academy of Medical Sciences

Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences

Department of Breast Surgery, Taian Tumor Hospital, Taian

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

AI问答

⁰